Cross-reactivity of TNP immune effector T cells that mediate contact hypersensitivity and inflammatory bowel disease in the mouse.
BACKGROUND
Experiments were aimed to test the cross-reactivity of immune Th1 cells that mediate contact hypersensitivity (CHS) or inflammatory bowel disease (IBD) to TNP in the mouse.


METHODS
CBA/J mice were immunized either epicutaneously or intrarectally with TNP and after appropriate time intervals were challenged with antigen in a crossed manner. The CHS reaction was measured by the ear swelling test. IBD was quantified by increase of colon weight and myeloperoxidase level. Both reactions were confirmed histologically. In passive-transfer experiments, mesenteric lymph node cells of animals sensitized intrarectally and peripheral lymph node and spleen cells of mice immunized epicutaneously were used. In some experiments, before being immunized mice were made either unresponsive to the TNP hapten by induction of suppressor T cells, or resistant to suppression after induction of upregulatory T cells.


RESULTS
Irrespective of the mode of sensitization upon appropriate challenge with antigen all mice developed a good CHS reaction as well as significant IBD. This cross-reactivity could be passively transferred by immune cells. In mice in which antigen-specific down- or upregulatory cells were induced before sensitization both CHS and IBD to TNP were modulated accordingly.


CONCLUSIONS
TNP hapten deposited on skin or on mucosal surfaces induces effector cells that recognize antigen independent of its tissue localization, and produce a local inflammatory reaction. TNP-specific up- and downregulatory cells, shown before to regulate the CHS reaction, similarly modulate the generation and development of hapten-induced IBD.
Ptak
W
W
Department of Immunology, College of Medicine, Jagiellonian University, Cracow, Poland.
Szczepanik
M
M
Bryniarski
K
K
Stachura
J
J
Gryglewski
A
A
Szewczyk
K
K
Ptak
M
M
D000818:Animals; D000941:Antigens / Q000008:administration & dosage; D003429:Cross Reactions; D003877:Dermatitis, Contact / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D006241:Haptens / Q000008:administration & dosage; D007116:Immunization, Passive; D015212:Inflammatory Bowel Diseases / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D018417:Th1 Cells / Q000276:immunology*; D014301:Trinitrobenzenes / Q000008:administration & dosage / Q000276:immunology*
D000941:Antigens; D006241:Haptens; D014301:Trinitrobenzenes